Abstract
Peptides regulate most physiological processes, mainly by binding to specific receptors located on the cell surface and inducing a series of signals, neurotransmissions or the release of growth factors. There has been a rapid expansion in the use of peptides as therapeutic agents after the 1960s, but a series of unfortunate side effects present in Phase I and II clinical studies combined with their low bioavailability, led to the introduction of the idea of peptidomimetics as alternative compounds that mimic the biological activity of peptides, while offering the advantages of increased bioavailability, biostability, bioefficiency, and bioselectivity. Since then new peptides with promising in vitro results, involving the monoclonal antibody expansion, as well as the newly launched research field for novel formulations for increasing peptides bioavailability, redirected the interest on the peptide market. In this report we will highlight three areas where the use of peptides has shown promising results, with products that are either currently used as drugs or included into Phase III clinical studies.
Keywords: Peptides, altered peptide ligands (APLs), cyclic peptide, hypertension, angiotensin, gonadotropin releasing Hormone (GnRH), multiple sclerosis (MS), immunotherapy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Peptides as Therapeutic Agents or Drug Leads for Autoimmune, Hormone Dependent and Cardiovascular Diseases
Volume: 7 Issue: 4
Author(s): Efthimia Mantzourani, Despoina Laimou, Minos Timotheos Matsoukas and Theodore Tselios
Affiliation:
Keywords: Peptides, altered peptide ligands (APLs), cyclic peptide, hypertension, angiotensin, gonadotropin releasing Hormone (GnRH), multiple sclerosis (MS), immunotherapy
Abstract: Peptides regulate most physiological processes, mainly by binding to specific receptors located on the cell surface and inducing a series of signals, neurotransmissions or the release of growth factors. There has been a rapid expansion in the use of peptides as therapeutic agents after the 1960s, but a series of unfortunate side effects present in Phase I and II clinical studies combined with their low bioavailability, led to the introduction of the idea of peptidomimetics as alternative compounds that mimic the biological activity of peptides, while offering the advantages of increased bioavailability, biostability, bioefficiency, and bioselectivity. Since then new peptides with promising in vitro results, involving the monoclonal antibody expansion, as well as the newly launched research field for novel formulations for increasing peptides bioavailability, redirected the interest on the peptide market. In this report we will highlight three areas where the use of peptides has shown promising results, with products that are either currently used as drugs or included into Phase III clinical studies.
Export Options
About this article
Cite this article as:
Mantzourani Efthimia, Laimou Despoina, Matsoukas Timotheos Minos and Tselios Theodore, Peptides as Therapeutic Agents or Drug Leads for Autoimmune, Hormone Dependent and Cardiovascular Diseases, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2008; 7 (4) . https://dx.doi.org/10.2174/187152308786847799
DOI https://dx.doi.org/10.2174/187152308786847799 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Long and Winding Road to Cancer Treatment: The Trail System
Current Pharmaceutical Design Antiproliferative and Proapoptotic Effects of Proteasome Inhibitors and their Combination with Histone Deacetylase Inhibitors on Leukemia Cells
Cardiovascular & Hematological Disorders-Drug Targets Cyclin-Dependent Kinase Inhibition by Flavoalkaloids
Mini-Reviews in Medicinal Chemistry Anethole Inhibits the Proliferation of Human Prostate Cancer Cells via Induction of Cell Cycle Arrest and Apoptosis
Anti-Cancer Agents in Medicinal Chemistry HPV Pathway Profiling: HPV Related Cervical Dysplasia and Carcinoma Studies
Current Pharmaceutical Design Utilising Nanotechnology and Nanosystems for Treatment of Rare Diseases
Pharmaceutical Nanotechnology Preventive and Therapeutic Role of Muscle Contraction Against Chronic Diseases
Current Pharmaceutical Design From Physiome to Pathome: A Systems Biology Model of Major Depressive Disorder and the Psycho-Immune-Neuroendocrine Network
Current Psychiatry Reviews Novel Chemotherapeutic Agents - The Contribution of Scorpionates
Current Medicinal Chemistry Recent Advances in GNAS Epigenetic Research of Pseudohypoparathyroidism
Current Molecular Medicine Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics
Current Medicinal Chemistry Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy
Current Medicinal Chemistry CYP3A4 *1B Gene Polymorphism in Coronary Artery Disease Patients with Obesity Undergoing Statin Treatment
Current Pharmacogenomics and Personalized Medicine Novel Folate-Hydroxamate Based Antimetabolites: Synthesis and Biological Evaluation
Medicinal Chemistry Cancer Prevention by Dietary Bioactive Components that Target the Immune Response
Current Cancer Drug Targets Anticancer Agent Ukrain and Bortezomib Combination is Synergistic in 4T1 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Nerve Growth Factor Receptors and Signaling in Breast Cancer
Current Cancer Drug Targets Chronic Inflammation and Colorectal Cancer: The Role of Vascular Endothelial Growth Factor
Current Pharmaceutical Design Identification and Targeting of Tumor Escape Mechanisms: A New Hope for Cancer Therapy?
Current Pharmaceutical Design Focal Adhesion Kinase Controls Prostate Cancer Progression Via Intrinsic Kinase and Scaffolding Functions
Anti-Cancer Agents in Medicinal Chemistry